Methods for treating hepatitis C
View Patent ↗In accordance with the present invention, compounds that can inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the invention, compounds useful in the treatment or prevention of HCV infection are provided.
1. A compound having the following formula:
wherein:
X is:
an amino;
Y is:
an oxadiazolyl substituted with:
a C 6 aryl optionally substituted with:
an alkoxy,
a halogen, or
a C 1 to C 6 alkyl; or
a 5- or 6-membered heteroaryl optionally substituted with:
an alkoxy,
a halogen, or
a C 1 to C 6 alkyl;
R is:
a haloalkyl;
a C 1 to C 6 alkyl optionally substituted with hydroxyl;
R 1 is:
a C 6 aryl;
a C 1 to C 6 alkyl;
a OCOR f where R f is a 5- or 6-membered heterocycle;
an alkoxy optionally substituted with an amino, wherein the amino is optionally substituted with one or two C 1 to C 6 alkyls, where the alkyls are optionally substituted with an amino optionally substituted with one or two C 1 to C 6 alkyls;
an alkoxy optionally substituted with a 5 to 8 membered heterocycle optionally substituted with a C 1 to C 6 alkyl, which is optionally substituted with:
an alkoxy; or
an amino, optionally substituted with one or two C 1 to C 6 alkyls;
R 2 is:
a C 1 to C 6 alkyl;
a 5- or 6-membered heterocycle;
an amino optionally substituted with a C 1 to C 6 alkyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein Y is
an oxadiazolyl substituted with:
a C 6 aryl optionally substituted with:
an alkoxy,
a halogen, or
a C 1 to C 6 alkyl, or
a 5- or 6-membered heteroaryl optionally substituted with a C 6 aryl optionally substituted with a halogen.
3. The compound of claim 1 , wherein R, R 1 and R 2 are independently C 1 to C 6 alkyl.
4. The compound of claim 3 , wherein said C 1 to C 6 alkyl in R, R 1 and R 2 is independently a methyl or an ethyl.
5. The compound of claim 1 , wherein R 1 is selected from the group consisting of
a C 1 to C 6 alkyl; and
an alkoxy optionally substituted with an amino, wherein the amino is optionally substituted with one or two C 1 to C 6 alkyls, where the alkyls are optionally substituted with an amino optionally substituted with one or two C 1 to C 6 alkyls; and
an alkoxy optionally substituted with a 5 to 8 membered heterocycle optionally substituted with a C 1 to C 6 alkyl, which is optionally substituted with:
an amino, optionally substituted with one or two C 1 to C 6 alkyls.
6. The compound of claim 1 , wherein said compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable excipient.
8. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient.
9. A pharmaceutical composition comprising a compound of claim 6 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient.
10. A method of treating Hepatitis C viral infection in a subject in need thereof comprising administering an effective amount of a compound of claim 1 to the subject.
11. A method of treating Hepatitis C viral infection in a subject in need thereof comprising administering an effective amount of a compound of claim 2 to the subject.
12. A method of treating Hepatitis C viral infection in a subject in need thereof comprising administering an effective amount of a compound of claim 6 to the subject.